Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT1806 SC vs RoActemra in Healthy Chinese Males
NCT05968508Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity, Area Under the Serum Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Aug 2023; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05968508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968508.